These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914 [TBL] [Abstract][Full Text] [Related]
4. Sung PS; Park DJ; Kim JH; Han JW; Lee EB; Lee GW; Nam HC; Jang JW; Bae SH; Choi JY; Shin EC; Park SH; Yoon SK Front Immunol; 2019; 10():1319. PubMed ID: 31244857 [TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for Chronic Hepatitis B Virus Infection. Bertoletti A; Le Bert N Gut Liver; 2018 Sep; 12(5):497-507. PubMed ID: 29316747 [TBL] [Abstract][Full Text] [Related]
6. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241 [TBL] [Abstract][Full Text] [Related]
7. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Lau GK; Cooksley H; Ribeiro RM; Powers KA; Shudo E; Bowden S; Hui CK; Anderson J; Sorbel J; Mondou E; Rousseau F; Lewin S; Perelson AS; Locornini S; Naoumov NV Antivir Ther; 2007; 12(5):705-18. PubMed ID: 17713154 [TBL] [Abstract][Full Text] [Related]
8. Immunopathogenesis of Hepatitis B Virus. Tseng TC; Huang LR J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047 [TBL] [Abstract][Full Text] [Related]
9. Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B. Zhang Z; Zhang JY; Wherry EJ; Jin B; Xu B; Zou ZS; Zhang SY; Li BS; Wang HF; Wu H; Lau GK; Fu YX; Wang FS Gastroenterology; 2008 Jun; 134(7):1938-49, 1949.e1-3. PubMed ID: 18455515 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-35 Suppresses Antiviral Immune Response in Chronic Hepatitis B Virus Infection. Shao X; Ma J; Jia S; Yang L; Wang W; Jin Z Front Cell Infect Microbiol; 2017; 7():472. PubMed ID: 29181338 [TBL] [Abstract][Full Text] [Related]
11. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B. Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859 [TBL] [Abstract][Full Text] [Related]
12. Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B. Xie Z; Protzer U Antiviral Res; 2024 Sep; 229():105972. PubMed ID: 39084340 [TBL] [Abstract][Full Text] [Related]
13. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082 [TBL] [Abstract][Full Text] [Related]
14. Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. Di Scala M; Otano I; Gil-Fariña I; Vanrell L; Hommel M; Olagüe C; Vales A; Galarraga M; Guembe L; Ortiz de Solorzano C; Ghosh I; Maini MK; Prieto J; González-Aseguinolaza G J Virol; 2016 Oct; 90(19):8563-74. PubMed ID: 27440883 [TBL] [Abstract][Full Text] [Related]
15. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Ma Z; Zhang E; Yang D; Lu M Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467 [TBL] [Abstract][Full Text] [Related]
16. TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. Boni C; Vecchi A; Rossi M; Laccabue D; Giuberti T; Alfieri A; Lampertico P; Grossi G; Facchetti F; Brunetto MR; Coco B; Cavallone D; Mangia A; Santoro R; Piazzolla V; Lau A; Gaggar A; Subramanian GM; Ferrari C Gastroenterology; 2018 May; 154(6):1764-1777.e7. PubMed ID: 29378197 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333 [TBL] [Abstract][Full Text] [Related]
18. Chronic hepatitis B virus in young adults: the need for new approaches to management. Gill US; Kennedy PT Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1045-53. PubMed ID: 25052517 [TBL] [Abstract][Full Text] [Related]
19. Emerging pipeline drugs for hepatitis B infection. Cox N; Tillmann H Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605 [TBL] [Abstract][Full Text] [Related]
20. Activating the innate immune response to counter chronic hepatitis B virus infection. Lamb C; Arbuthnot P Expert Opin Biol Ther; 2016 Dec; 16(12):1517-1527. PubMed ID: 27603796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]